Erratum to “Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients”

This study aimed to explore efficient ways to diagnose bone metastasis early using bone scintigraphy images through negative mining, pre-training, the convolutional neural network, and deep learning. We studied 205 prostate cancer patients and 371 breast cancer patients and used bone scintigraphy data from breast cancer patients to pre-train a YOLO v4 with a false-positive reduction strategy. With the pre-trained model, transferred learning was applied to prostate cancer patients to build a model to detect and identify metastasis locations using bone scintigraphy. Ten-fold cross validation was conducted. The mean sensitivity and precision rates for bone metastasis location detection and classification (lesion-based) in the chests of prostate patients were 0.72 ± 0.04 and 0.90 ± 0.04, respectively. The mean sensitivity and specificity rates for bone metastasis classification (patient-based) in the chests of prostate patients were 0.94 ± 0.09 and 0.92 ± 0.09, respectively. The developed system has the potential to provide pre-diagnostic reports to aid in physicians’ final decisions.

Download Full-text

Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: Influence of Gleason score, treatment and bone metastasis

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2012.12.004 ◽

2013 ◽

Vol 67 (3) ◽

pp. 203-208 ◽

Cited By ~ 10

Author(s):

Vanessa Battisti ◽

Liési D.K. Maders ◽

Margarete D. Bagatini ◽

Iara E. Battisti ◽

Luziane P. Bellé ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Adenosine Deaminase ◽

Cancer Patients ◽

Gleason Score

Download Full-text

Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.02.9439 ◽

2006 ◽

Vol 24 (13) ◽

pp. 1982-1989 ◽

Cited By ~ 58

Author(s):

Norihiko Tsuchiya ◽

Lizhong Wang ◽

Hiroyoshi Suzuki ◽

Takehiko Segawa ◽

Hisami Fukuda ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Genetic Polymorphisms ◽

Metastatic Prostate Cancer ◽

Genetic Factors ◽

Response To Treatment ◽

Logrank Test ◽

Ca Repeat ◽

Igf I

Purpose The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. Patients and Methods One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. Results Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). Conclusion The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.

Download Full-text

Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis

BMC Cancer ◽

10.1186/1471-2407-13-150 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 7

Author(s):

Norihiko Tsuchiya ◽

Shintaro Narita ◽

Takamitsu Inoue ◽

Mitsuru Saito ◽

Kazuyuki Numakura ◽

...

Keyword(s):

Prostate Cancer ◽

Growth Factor ◽

Bone Metastasis ◽

Cancer Patients ◽

Initial Diagnosis ◽

Insulin Like Growth Factor

Download Full-text

Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines

Journal of Nuclear Medicine ◽

10.2967/jnumed.119.230318 ◽

2019 ◽

Vol 61 (3) ◽

pp. 405-411 ◽

Cited By ~ 4

Author(s):

Kelsey L. Pomykala ◽

Johannes Czernin ◽

Tristan R. Grogan ◽

Wesley R. Armstrong ◽

John Williams ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Bone Scan ◽

Pet Ct ◽

Potential Impact ◽

Total Body

Download Full-text

Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data

Experimental and Therapeutic Medicine ◽

10.3892/etm_00000099 ◽

2010 ◽

Vol 1 (4) ◽

pp. 635-639 ◽

Cited By ~ 3

Author(s):

YOSHIAKI YAMADA ◽

KATSUYA NARUSE ◽

KOGENTA NAKAMURA ◽

TOMOHIRO TAKI ◽

MOTOI TOBIUME ◽

...

Keyword(s):

Prostate Cancer ◽

Risk Factors ◽

Bone Metastasis ◽

Cancer Patients ◽

Clinical Data

Download Full-text

Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients

Contrast Media & Molecular Imaging ◽

10.1155/2018/9840962 ◽

2018 ◽

Vol 2018 ◽

pp. 1-12 ◽

Cited By ~ 6

Author(s):

Manuel Scimeca ◽

Nicoletta Urbano ◽

Bonfiglio Rita ◽

Sarah Natalia Mapelli ◽

Carlo Vittorio Catapano ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Cancer Cells ◽

Cancer Patients ◽

Clinical Evidence ◽

Prostate Cancer Cells ◽

Ultrastructural Studies ◽

Pet Ct ◽

Ct Analysis ◽

Malignant Lesions

The main aim of this study was to investigate the putative association among the presence of prostate cancer cells, defined as prostate osteoblast-like cells (POLCs), and showing the expression of typical morphological and molecular characteristics of osteoblasts, the development of bone metastasis within 5 years of diagnosis, and the uptake of 18F-choline evaluated by PET/CT analysis. To this end, prostate biopsies (n= 110) were collected comprising 44 benign lesions and 66 malignant lesions. Malignant lesions were further subdivided into two groups: biopsies from patients that had clinical evidence of bone metastasis (BM+,n= 23) and biopsies from patients that did not have clinical evidence of bone metastasis within 5 years (BM−,n= 43). Paraffin serial sections were obtained from each specimen to perform histological classifications and immunohistochemical (IHC) analysis. Small fragments of tissue were used to perform ultrastructural and microanalytical investigations. IHC demonstrated the expression of markers of epithelial-to-mesenchymal transition (VIM), bone mineralization, and osteoblastic differentiation (BMP-2, PTX-3, RUNX2, RANKL, and VDR) in prostate lesions characterized by the presence of calcium-phosphate microcalcifications and high metastatic potential. Ultrastructural studies revealed the presence of prostate cancer cells with osteoblast phenotype close to microcalcifications. Noteworthy, PET/CT analysis showed higher uptake of 18F-choline in BM+ lesions with high positivity (≥300/500 cells) for RUNX2 and/or RANKL immunostaining. Although these data require further investigations about the molecular mechanisms of POLCs generation and role in bone metastasis, our study can open new and interesting prospective in the management of prostate cancer patients. The presence of POLCs along with prostate microcalcifications may become negative prognostic markers of the occurrence of bone metastases.

Download Full-text